Bartesaghi R - Search Results

1

Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome.

Ravaioli F, Stagni F, Guidi S, Pirazzini C, Garagnani P, Silvani A, Zoccoli G, Bartesaghi R, Bacalini MG. Ravaioli F, et al. Among authors: bartesaghi r. Front Aging Neurosci. 2024 May 21;16:1401109. doi: 10.3389/fnagi.2024.1401109. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38836050 Free PMC article.

2

Reversal of neurodevelopmental impairment and cognitive enhancement by pharmacological intervention with the polyphenol polydatin in a Down syndrome model.

Emili M, Stagni F, Russo C, Angelozzi L, Guidi S, Bartesaghi R. Emili M, et al. Among authors: bartesaghi r. Neuropharmacology. 2024 Dec 15;261:110170. doi: 10.1016/j.neuropharm.2024.110170. Epub 2024 Sep 27. Neuropharmacology. 2024. PMID: 39341334

3

Translating molecular advances in Down syndrome and Fragile X syndrome into therapies.

Faundez V, De Toma I, Bardoni B, Bartesaghi R, Nizetic D, de la Torre R, Cohen Kadosh R, Herault Y, Dierssen M, Potier MC; Down Syndrome and Other Genetic Developmental Disorders ECNP Network. Faundez V, et al. Among authors: bartesaghi r. Eur Neuropsychopharmacol. 2018 Jun;28(6):675-690. doi: 10.1016/j.euroneuro.2018.03.006. Epub 2018 Jun 7. Eur Neuropsychopharmacol. 2018. PMID: 29887288 Review.

4

Cellularity Defects Are Not Ubiquitous in the Brains of Fetuses With Down Syndrome.

Emili M, Stagni F, Bonasoni MP, Guidi S, Bartesaghi R. Emili M, et al. Among authors: bartesaghi r. Dev Neurobiol. 2024 Oct;84(4):264-273. doi: 10.1002/dneu.22953. Epub 2024 Sep 30. Dev Neurobiol. 2024. PMID: 39344402

5

Brain circuit pathology in Down syndrome: from neurons to neural networks.

Bartesaghi R. Bartesaghi R. Rev Neurosci. 2022 Sep 29;34(4):365-423. doi: 10.1515/revneuro-2022-0067. Print 2023 Jun 27. Rev Neurosci. 2022. PMID: 36170842 Free article. Review.

6

Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?

Martínez-Cué C, Bartesaghi R. Martínez-Cué C, et al. Among authors: bartesaghi r. Nutrients. 2022 Jul 13;14(14):2880. doi: 10.3390/nu14142880. Nutrients. 2022. PMID: 35889838 Free PMC article. Review.

7

The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives.

Stagni F, Bartesaghi R. Stagni F, et al. Among authors: bartesaghi r. Front Cell Neurosci. 2022 May 11;16:903729. doi: 10.3389/fncel.2022.903729. eCollection 2022. Front Cell Neurosci. 2022. PMID: 35634470 Free PMC article. Review.

8

Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone.

Valenti D, Stagni F, Emili M, Guidi S, Bartesaghi R, Vacca RA. Valenti D, et al. Among authors: bartesaghi r. Antioxidants (Basel). 2021 Dec 28;11(1):62. doi: 10.3390/antiox11010062. Antioxidants (Basel). 2021. PMID: 35052567 Free PMC article.

9

Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders.

Bartesaghi R, Vicari S, Mobley WC. Bartesaghi R, et al. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:211-233. doi: 10.1146/annurev-pharmtox-041521-103641. Annu Rev Pharmacol Toxicol. 2022. PMID: 34990205 Free PMC article.

10

Early Appearance of Dendritic Alterations in Neocortical Pyramidal Neurons of the Ts65Dn Model of Down Syndrome.

Uguagliati B, Stagni F, Emili M, Giacomini A, Russo C, Guidi S, Bartesaghi R. Uguagliati B, et al. Among authors: bartesaghi r. Dev Neurosci. 2022;44(1):23-38. doi: 10.1159/000520925. Epub 2021 Dec 1. Dev Neurosci. 2022. PMID: 34852343

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters